Entera Bio Publishes Key Study Describing its Oral Delivery Technology Platform for Biologic DrugsGlobeNewsWire • 10/28/21
Entera Bio Presents Positive Phase 2 6-Month Bone Mineral Density Data for Oral PTH Formulation at Late Breaker ASBMR Conference SessionGlobeNewsWire • 10/06/21
Entera Bio Selected for Late Breaking Oral Presentation of Phase 2 6-Month Osteoporosis Data at ASBMR 2021 Annual MeetingGlobeNewsWire • 09/01/21
Entera Bio to Present at H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewsWire • 08/23/21
Entera Bio Ltd. (ENTX) CEO Spiros Jamas on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/16/21
Entera Bio Reports Second Quarter 2021 Financial Results and Provides Clinical UpdatesGlobeNewsWire • 08/16/21
Entera Bio to Report Business and Financial Results for the Quarter ended June 30, 2021, on August 16, 2021GlobeNewsWire • 08/13/21
Entera Bio to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment 3-Month Findings at the American Society for Bone and Mineral Research Annual MeetingGlobeNewsWire • 08/02/21
Entera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613 Positioned to be the First Oral Bone-Building Agent for the Treatment of OsteoporosisGlobeNewsWire • 06/28/21
Entera Bio Announces Excellent Topline Phase 2 BMD Data for EB613, the Study Met Its Primary and Key Secondary EndpointsGlobeNewsWire • 06/23/21
Entera Bio Reports First Quarter 2021 Financial Results and Provides Clinical UpdatesGlobeNewsWire • 05/20/21